Eli Lilly's expansion of clinical trials for its weight-loss drugs to non-obese patients could open new markets and increase demand, potentially boosting revenue. The company's stance against off-label use for cosmetic purposes aligns with ethical marketing, which may enhance its reputation. The stock's recent price increase suggests positive investor sentiment.